See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eid
Natural Disasters
Social Media
Baseball
Earthquake
Artificial Intelligence
Tennis
Donald Trump
Taxes
European Union
Soccer
Stock Markets
Published • loading... • Updated

Chemoimmunotherapy Vs Standard Chemoradiotherapy in ESCC: Is One Better?

Summary by Medscape
Neoadjuvant chemoimmunotherapy is associated with significantly improved survival outcomes compared with standard chemoradiotherapy in patients with locally advanced ESCC. Medscape Medical News

1 Articles

All
Left
Center
Right
MedscapeMedscape

Chemoimmunotherapy Vs Standard Chemoradiotherapy in ESCC: Is One Better?

Neoadjuvant chemoimmunotherapy is associated with significantly improved survival outcomes compared with standard chemoradiotherapy in patients with locally advanced ESCC. Medscape Medical News

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medscape broke the news in United States on Wednesday, March 26, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Medical

Medical

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal